Head to head
Vosoritide against Navepegritide
Two C-type natriuretic peptide drugs for achondroplasia, one daily and one weekly, both FDA-approved. Both were approved on growth velocity rather than final adult height, which is the measurement families most want and the one neither trial could deliver.
Column A
VosoritideVosoritide (Voxzogo), C-type natriuretic peptide analogue
A C-type natriuretic peptide analogue approved for achondroplasia on a randomised phase 3. It increases growth velocity by roughly 1.6 cm a year, and nobody knows the effect on final adult height.
Column B
NavepegritideNavepegritide (TransCon CNP, Yuviwel)
A once-weekly prodrug of C-type natriuretic peptide, FDA-approved in February 2026 for achondroplasia in children aged two and older.
Side by side, on the facts we can check
| Attribute | Vosoritide | Navepegritide |
|---|---|---|
| Category | Growth Hormone | Hormone |
| FDA status | FDA-approved as Voxzogo to increase linear growth in children with achondroplasia with open epiphyses. Approval rests on growth velocity, not final adult height. | FDA-approved (accelerated) for achondroplasia, 2026 |
| Half-life | Roughly 20 to 30 minutes, very short, which is why it requires daily subcutaneous injection despite being engineered for stability against neutral endopeptidase. | Weekly dosing (prodrug release) |
| Molecular weight | Roughly 4.1 kDa. A 39-amino-acid peptide. | No single molecular weight: a CNP peptide conjugated to a PEG carrier of indefinite length (KEGG lists the peptide plus an indefinite PEG term) |
| Mechanism | A 39-amino-acid analogue of C-type natriuretic peptide, modified to resist degradation by neutral endopeptidase, which destroys the native peptide within minutes. It binds natriuretic peptide receptor B, raising cyclic GMP and activating protein kinase G, which inhibits the RAF and MEK and ERK cascade at the level of RAF-1. In achondroplasia, an activating FGFR3 mutation drives that same MAPK cascade too hard and suppresses chondrocyte proliferation in the growth plate. So vosoritide works by braking the pathway the mutation over-accelerates, which is antagonism downstream of the defect rather than correction of it. | Sustained-release CNP analog that stimulates natriuretic peptide receptor B, inhibiting the MAPK pathway downstream of FGFR3 in growth-plate cartilage. |
| Human studies cited | 1 | 2 |
| Legal status, US | FDA-approved, prescription only | FDA-approved (achondroplasia), prescription only |
Frequently asked questions
What is the difference between Vosoritide and Navepegritide?
Vosoritide: A C-type natriuretic peptide analogue approved for achondroplasia on a randomised phase 3. It increases growth velocity by roughly 1.6 cm a year, and nobody knows the effect on final adult height. Navepegritide: A once-weekly prodrug of C-type natriuretic peptide, FDA-approved in February 2026 for achondroplasia in children aged two and older.
Which has stronger research evidence, Vosoritide or Navepegritide?
This database does not grade compounds. It counts what was run in people: 1 of the 1 studies cited on the Vosoritide profile were human work, against 2 of 2 for Navepegritide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Vosoritide and Navepegritide FDA-approved?
Vosoritide: FDA-approved as Voxzogo to increase linear growth in children with achondroplasia with open epiphyses. Approval rests on growth velocity, not final adult height.. Navepegritide: FDA-approved (accelerated) for achondroplasia, 2026.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.